Venture Kick

Clee Medical specializes in developing innovative neuroimaging and surgical access technologies to improve precision and efficiency in neurosurgery. Their products, which include imaging and sensing systems, provide enhanced access, vision, and navigation within the brain, seamlessly integrating with existing neurosurgical equipment and current surgical routines. This enables healthcare providers to potentially enhance patient outcomes with greater precision.

Scanvio develops AI-augmented ultrasound software for enhanced endometriosis diagnosis. It empowers gynecologists with expert sonography skills, aiming to improve healthcare outcomes and surgical education.

BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments

Shape Biopharmaceuticals is a biotechnology company that specializes in the development of immunotherapeutic drugs aimed at treating chronic diseases with limited treatment options. The company focuses on advanced protein design and formulation technologies to create a new generation of immunotherapies. By addressing unmet medical needs, Shape Biopharmaceuticals seeks to improve patient outcomes for individuals with genetically driven conditions who lack effective therapeutic alternatives. Through its innovative healthcare solutions, the company aims to provide hope and enhance treatment possibilities for patients facing significant health challenges.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

Pace Locator is a medical technology company that specializes in developing advanced imaging software. Its flagship product, also named Pace Locator, uses electrocardiogram (ECG) and echocardiogram (ECHO) data to generate 3D maps of the heart. This innovative tool helps healthcare professionals localize the source of cardiac arrhythmias and visualize the location of cardiac implantable electronic device (CIED) leads, enabling faster and more accurate diagnoses.

Procavea Biotech specializes in developing a drug delivery system based on non-viral protein cages for targeted therapeutic applications.

HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.

Rhovica Neuroimaging specializes in innovative neuroimaging technology designed to optimize emergency treatment for patients with elevated intracranial pressure. Its primary product is a device that facilitates precise and rapid placement of external ventricular drains, enabling real-time monitoring post-insertion. This innovation aims to improve patient outcomes, reduce procedural complications, and potentially lower healthcare costs by streamlining critical neurological interventions.

Ocumeda operates a telemedical network of ophthalmologists, offering accessible eye examinations in collaboration with opticians, retirement homes, and companies. Their services include remote consultations and on-site assessments, enabling early detection and treatment of eye diseases to prevent vision loss.

Developer of a metabolic health assessment platform designed to support healthcare professionals in identifying at-risk individuals before traditional diagnostics. The company uses saliva-based metabolite measurements analyzed through customized Nuclear Magnetic Resonance (NMR) spectrometry, enabling registered nutritionists and healthcare providers to assess metabolic health with minimal invasiveness, competitive cost, and early detection capabilities.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on Endometriosis. The company aims to accelerate the path toward a cure for endometriosis by addressing significant healthcare requirements and advancing novel ideas in women's health. FimmCyte's mission is to empower women to take control of their health and meet their unmet medical needs through cutting-edge treatments.

OptimaRatio liberates chronic and rare disease patients from managing their complex health data.

Rhovica Neuroimaging specializes in innovative neuroimaging technology designed to optimize emergency treatment for patients with elevated intracranial pressure. Its primary product is a device that facilitates precise and rapid placement of external ventricular drains, enabling real-time monitoring post-insertion. This innovation aims to improve patient outcomes, reduce procedural complications, and potentially lower healthcare costs by streamlining critical neurological interventions.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Simulatory is a developer of a virtual endoscopic spine surgery simulator designed to train surgeons in ultra-minimally invasive endoscopic techniques for spinal surgery. The platform uses machine learning and artificial intelligence to provide unlimited training opportunities on lifelike anatomical models, enabling surgeons to practice safely in a data-driven space and to refine practical surgical skills.

Rhovica Neuroimaging specializes in innovative neuroimaging technology designed to optimize emergency treatment for patients with elevated intracranial pressure. Its primary product is a device that facilitates precise and rapid placement of external ventricular drains, enabling real-time monitoring post-insertion. This innovation aims to improve patient outcomes, reduce procedural complications, and potentially lower healthcare costs by streamlining critical neurological interventions.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Bottneuro is a company focused on developing innovative therapies for early to moderate-stage Alzheimer's Disease patients. Utilizing its proprietary NENI technology platform, Bottneuro creates non-invasive stimulation protocols that target neurons and glial cells in the brain. In addition to its work in Alzheimer's treatment, the company has developed a brain therapy system designed to alleviate chronic neuropathic pain. This system employs plant-based components and features a 3D printed cap that allows for continuous monitoring and targeted delivery of active substances within the body. By addressing the specific needs of patients with early to mild Alzheimer's disease, Bottneuro aims to enhance their quality of life through improved treatment options and medical care.

InnoSpina is a medical device company focused on developing innovative 3D printed implants and specialized surgical guiding instruments for the treatment of chronic back pain. The company's products are designed to facilitate minimally invasive and motion-preserving procedures for spinal disorders. By offering intuitive guiding instruments and novel implants, InnoSpina empowers spine surgeons and interventional pain management specialists to achieve safe and accurate positioning during surgery. This approach not only simplifies the surgical process but also significantly reduces the operative time, allowing for more efficient treatment of patients suffering from back pain.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.

Founded in 2020, Resmonics is a spin-off from ETH Zürich and University St. Gallen. It specializes in acoustic artificial intelligence that analyzes room soundscapes to detect symptoms of infectious lung diseases. Its product line, Quorum, combines this AI with air quality sensors and noise analytics to create healthy work environments.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

aiEndoscopic is a MedTech start-up focused on enhancing the safety and simplicity of tracheal intubations through the integration of robotics and artificial intelligence. The company manufactures advanced medical devices that offer visual access and precision, allowing for assistive or autonomous endoscopy. This innovative approach enables surgeons to perform intubation and various surgical procedures more effectively, significantly reducing risks to patients' lives. By streamlining the intubation process, aiEndoscopic aims to improve surgical outcomes and enhance the overall efficiency of medical practices.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

4iLabs is developing a diagnostic toolbox to support clinicians in the therapy decision-making process for patients with progressed cancer beyond the standard of care.

Axentless develops software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.

Abologix is a biopharmaceutical company focused on developing innovative therapeutics for oncology treatment. The company specializes in creating best-in-class monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. These treatments are specifically designed for patients who do not respond to conventional cancer therapies, aiming to provide new options for those with various oncological medical conditions. Abologix's approach reflects a commitment to advancing cancer care through the development of novel therapeutic solutions.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Nutrix is a Swiss health-technology company focused on prevention and precision medicine. It develops a non-invasive nanosensor placed on the tooth to measure glucose levels in saliva, with data transmitted to an external application. The sensor tracks food intake and provides dietary guidance to help prevent diabetes. The company combines artificial intelligence with wearables and human care to deliver cost-effective prevention and healthcare programs, including digital coaching and telemedicine, enabling caregivers to monitor patients remotely and reduce routine doctor visits. In 2025 Nutrix expanded its offering with CortiSense, a cortisol monitoring sensor, reflecting its move into non-invasive hormonal monitoring. Based in Basel, Switzerland, Nutrix provides an integrated solution of sensors, software, and care services.

Flowbone develops and promotes an injectable biomaterial for minimally invasive augmentation of fragile bones at high risk of fracture. Its treatment strengthens bone without impeding mechanics or blood flow, aiming to improve independence and quality of life among the elderly by preventing fragility fractures.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.

Founded in 2020, SurgeonsLab specializes in developing patient-specific training models for surgical procedures. It offers microsurgical treatment planning, procedure planning, and validation of new medical devices to enhance precision and safety in surgeries.

Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.

Inanna develops a clinical decision assistance platform designed to enhance outcomes in in-vitro fertility treatments. The platform employs machine learning algorithms and a global patient database to offer data-driven insights for personalized treatment recommendations, adaptively adjusted based on each patient's medical history and response.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.

Testmate Health is a medtech startup and award-winning spin-off of the University of Geneva in Switzerland. It has developed a smartphone-compatible platform test kit capable of diagnosing diseases based on identifiable DNA or RNA sequences without the need for a laboratory, delivering results in minutes at home. The initial product is a rapid urine self-test for the four most common sexually transmitted infections, designed to be used outside clinical settings and to provide a smartphone-scanable result that supports immediate access to treatment if needed. The platform uses DNA isothermal technology to detect infectious diseases with identifiable DNA, enabling home testing without laboratory submission. Further test kits for additional diseases are in development to empower users to monitor their health from home.

Endotelix is a Swiss biotechnology company and a spin-off from the University of Geneva focused on antiphospholipid syndrome. It develops diagnostic tests and treatment options, aiming to deliver fast, sensitive solutions for the condition. The company provides diagnostic tools, therapies, and supports clinical research to assist clinicians in diagnosing antiphospholipid syndrome and identifying effective treatments.

Founded in 2019, Swiss Medical Union specializes in developing and manufacturing advanced bioreactor systems for testing new medical products' interaction, efficiency, and safety using human organ and tissue models. The company offers a software suite to simulate organ activity, analyze product-organ interactions, and monitor effects in real-time. Additionally, they provide clinical testing services to hospitals, healthcare institutions, and international facilities.

MaxWell Biosystems is a neuroscience-focused electronics and biotechnology company that develops instrumentation and solutions to advance neuroscience research and accelerate preclinical drug discovery. It provides functional cell imaging and electrophysiology platforms to study cellular function and network activity. The flagship MaxOne platform is a CMOS-based high-density microelectrode array that records and stimulates electrogenic cells in vitro, featuring thousands of electrodes, low-noise readout channels and multiple stimulation channels to enable single-cell and network parameter extraction for phenotypic screening and drug toxicity and efficacy testing. The integrated platform combines a sensor chip, acquisition hardware and software to deliver accurate results and speed up the characterization of cell function from months to weeks. The company, founded in 2016, is based in Zurich, Switzerland.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

ELDICO Scientific AG is a Swiss company founded in 2019 and located at the Switzerland Innovation Park Innovaare, which is affiliated with the Paul Scherrer Institute. The company specializes in the development, manufacturing, and sale of electron diffractometers designed for the analysis of solid compounds, particularly targeting nano-crystalline systems in the sub-micrometer range. ELDICO's innovative instruments enable industrial and scientific researchers to characterize materials that were previously challenging to measure, thereby facilitating advancements in fields such as pharmaceuticals, agrochemicals, and advanced materials research. The company achieved proof of concept for its technology in 2018, with recognition from reputable scientific communities, including being named a Top 5 "Breakthrough of the Year" by a leading journal. This groundbreaking work positions ELDICO as a key player in enhancing the speed and cost-effectiveness of structural analysis, ultimately contributing to faster drug discovery and development processes.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

Microcaps develops microencapsulation technology that protects and controls the release of active ingredients in pharmaceuticals, probiotics, and cosmetic formulations. Leveraging microfluidics and step emulsification, the company produces monodisperse microcapsules and microparticles at scale, enabling precise size control, dosing, and greater stability. Its platform supports liquid oil core microcapsules with natural alginate shells, improving throughput without quality loss. Based in Zurich, Switzerland, Microcaps targets applications across drug delivery, probiotic encapsulation, and fragrance or cosmetic encapsulation, offering automated encapsulation production capable of high-throughput manufacturing for complex formulations.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

Endotelix is a Swiss biotechnology company and a spin-off from the University of Geneva focused on antiphospholipid syndrome. It develops diagnostic tests and treatment options, aiming to deliver fast, sensitive solutions for the condition. The company provides diagnostic tools, therapies, and supports clinical research to assist clinicians in diagnosing antiphospholipid syndrome and identifying effective treatments.

Alibion AG is a therapeutics development company founded in 2018 and located in Allschwil, Switzerland. The company aims to bridge the gap between academic drug discoveries and patient access by accelerating the early-stage development of novel therapeutics. Recognizing that many promising therapies developed in academic settings often fail to progress to preclinical and clinical testing due to a lack of development partners, Alibion focuses on identifying and advancing these innovative compounds. By pooling necessary resources and managing drug development through outsourced partners, Alibion seeks to streamline processes, reduce costs, and ensure compliance with quality standards. Ultimately, the company is dedicated to improving patient outcomes globally by facilitating the transition of new therapies from labs to late-stage development.

Anavo Medical is a developer of innovative pharmaceutical products utilizing advanced nanotechnology to enhance wound healing and reduce complications associated with skin grafts. The company's flagship offering is a nanoparticle-based paste that contains bioactive nanoparticles suspended in a user-friendly matrix. These nanoparticles, which include metal oxides, possess anti-inflammatory and neo-angiogenic properties that promote the regeneration of blood vessels and mitigate inflammation. By leveraging these capabilities, Anavo Medical aims to improve patient safety and outcomes in surgical procedures, particularly in the healthcare and skin transplant sectors, thereby facilitating quicker healing and minimizing the risk of complications related to skin transplantation.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.

Genknowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in personalized epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By utilizing DNA methylation biomarkers, Genknowme quantifies how various elements such as diet, physical activity, tobacco use, and alcohol consumption affect an individual's health. The company's innovative platform provides health-conscious individuals with actionable insights, empowering them to make informed decisions about their lifestyle and seek proactive care based on their genetic predispositions.

Endotelix is a Swiss biotechnology company and a spin-off from the University of Geneva focused on antiphospholipid syndrome. It develops diagnostic tests and treatment options, aiming to deliver fast, sensitive solutions for the condition. The company provides diagnostic tools, therapies, and supports clinical research to assist clinicians in diagnosing antiphospholipid syndrome and identifying effective treatments.

Hi-D Imaging AG is a Swiss company established in 2019, specializing in advanced imaging technologies for cardiovascular disease, particularly focusing on heart valve replacement. The company offers a SaaS-based pre-operational planning platform that assesses the hemodynamics of patient-specific anatomies. This platform enables physicians to analyze blood flow patterns and select the optimal size and shape of heart valves prior to trans-catheter aortic valve implantation. By providing detailed imaging and in-vitro fluid dynamic analysis, Hi-D Imaging empowers medical professionals to make data-driven decisions tailored to individual patient needs, thereby improving surgical outcomes and reducing the necessity for additional medical imaging. The company is headquartered in Winterthur, Switzerland.

b-rayZ is a spin-off from University Hospital Zurich that develops artificial intelligence tools for medical imaging. Its team blends radiologists, data scientists and physicians with extensive experience in imaging and radiology. The company creates predictive deep learning analytics to assess personal medical images and to support radiologists in mammography by providing real-time image quality and breast density assessments. The software enables standardized evaluation of imaging data to improve breast cancer detectability and aims to enhance diagnostic accuracy and efficiency, potentially reducing healthcare costs.

Microcaps develops microencapsulation technology that protects and controls the release of active ingredients in pharmaceuticals, probiotics, and cosmetic formulations. Leveraging microfluidics and step emulsification, the company produces monodisperse microcapsules and microparticles at scale, enabling precise size control, dosing, and greater stability. Its platform supports liquid oil core microcapsules with natural alginate shells, improving throughput without quality loss. Based in Zurich, Switzerland, Microcaps targets applications across drug delivery, probiotic encapsulation, and fragrance or cosmetic encapsulation, offering automated encapsulation production capable of high-throughput manufacturing for complex formulations.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

Aspivix develops innovative medical devices aimed at enhancing safety and comfort in gynecological procedures. Its flagship product, CAREVIX, employs suction technology to gently stabilize the cervix during procedures, reducing pain and minimizing risks such as bleeding and infections.

Founded in 2018, SEED Biosciences specializes in developing innovative solutions for single-cell assays. Its flagship product, DispenCell, is a compact pipetting robot designed to precisely isolate single cells, enabling scientists to streamline workflows and enhance experimental accuracy.

MOMM Diagnostics is a Basel-based medical technology company founded in 2018 that develops a novel in vitro diagnostic test and device for the early diagnosis of preeclampsia at the point of care, enabling earlier detection of pregnancy-related risks and improved maternal and fetal management.

ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in creating non-invasive assays aimed at the screening, diagnosis, and monitoring of oncological diseases. The company's initial product is a urine assay designed specifically for the screening of prostate cancer. By focusing on innovative diagnostic solutions, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Microcaps develops microencapsulation technology that protects and controls the release of active ingredients in pharmaceuticals, probiotics, and cosmetic formulations. Leveraging microfluidics and step emulsification, the company produces monodisperse microcapsules and microparticles at scale, enabling precise size control, dosing, and greater stability. Its platform supports liquid oil core microcapsules with natural alginate shells, improving throughput without quality loss. Based in Zurich, Switzerland, Microcaps targets applications across drug delivery, probiotic encapsulation, and fragrance or cosmetic encapsulation, offering automated encapsulation production capable of high-throughput manufacturing for complex formulations.

Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.

Founded in 2018, SEED Biosciences specializes in developing innovative solutions for single-cell assays. Its flagship product, DispenCell, is a compact pipetting robot designed to precisely isolate single cells, enabling scientists to streamline workflows and enhance experimental accuracy.

ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in creating non-invasive assays aimed at the screening, diagnosis, and monitoring of oncological diseases. The company's initial product is a urine assay designed specifically for the screening of prostate cancer. By focusing on innovative diagnostic solutions, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.

Aspivix develops innovative medical devices aimed at enhancing safety and comfort in gynecological procedures. Its flagship product, CAREVIX, employs suction technology to gently stabilize the cervix during procedures, reducing pain and minimizing risks such as bleeding and infections.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Rapid Graft, established in 2018 and based in Zurich, Switzerland, specializes in developing innovative medical devices for precise skin graft harvesting. Their flagship product is a novel dermatome designed to efficiently obtain small split-skin grafts, aiming to enhance chronic wound treatment and facilitate future tissue engineering needs. The company's device enables surgeons to perform skin grafting procedures more effectively, minimizing the risk of infection, scarring, and requiring fewer specialized interventions or operating room resources.

Founded in 2018, SEED Biosciences specializes in developing innovative solutions for single-cell assays. Its flagship product, DispenCell, is a compact pipetting robot designed to precisely isolate single cells, enabling scientists to streamline workflows and enhance experimental accuracy.

Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

Aspivix develops innovative medical devices aimed at enhancing safety and comfort in gynecological procedures. Its flagship product, CAREVIX, employs suction technology to gently stabilize the cervix during procedures, reducing pain and minimizing risks such as bleeding and infections.

SNAQ GmbH is a Zurich-based company specializing in mobile applications that utilize machine learning and computer vision for food recognition and portion size calculation. The application allows users to send images of their meals, identifying each food item and determining its portion size. By linking this information with a comprehensive nutrition database, SNAQ provides detailed nutritional insights, including carbohydrate, calorie, and protein content for various meals. The company's innovative end-to-end solution has garnered attention and has been showcased at several diabetes conferences across Europe, demonstrating its commitment to enhancing health and lifestyle through technology.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

Liberty MedTech will solve a vital problem to all person affected with mobility problem with a simple revolutionary solution.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of advanced tissue reconstruction technologies tailored for the reconstructive and plastic surgery markets. The company focuses on tissue engineering, creating injectable 3D scaffolds that facilitate the reconstruction of lost soft tissue volumes due to tumor ablation, disease, trauma, or aesthetic needs. These innovative scaffolds can be administered through thin cannulas, which helps reduce both intervention and recovery times for patients, addressing the challenges associated with the natural repair of three-dimensional soft tissues.

Aesyra is a Swiss medical device company based in Lausanne that designs and commercializes intra-oral sensors and compact oral appliances to monitor and manage sleep-related conditions such as bruxism and obstructive sleep apnea. The company develops devices that embed sensors to collect and display metrics, enabling dental professionals to reduce occlusal damages to dental prostheses and helping individuals pursue better sleep. Its offerings include an oral appliance with a customizable liner for optimal fit and sensor-enabled monitoring and management tools for clinicians and patients.

Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.